Medical News

RSS

Health experts gather in Ethiopia to discuss child, maternal health in Africa

A group of health experts gathered in Addis Ababa, Ethiopia, Monday, to kick off a continental conference on maternal and child health, VOA News reports (Heinlein, 4/19).

21 Apr 2010

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.

21 Apr 2010

Cannabis users are at risk for developing anxiety and mood disorders: CAMH study

Research has shown possible links between cannabis use and the onset of Schizophrenia, but a new study from the Centre for Addiction and Mental Health shows that people who use cannabis may also be at risk for developing anxiety and mood disorders.

21 Apr 2010

Abbott to purchase all outstanding shares of Facet Biotech

Abbott today announced the successful completion of the tender offer by its wholly owned subsidiary Amber Acquisition Inc. to purchase all of the outstanding shares of common stock of Facet Biotech.

21 Apr 2010

Australia heading for its own health overhaul

Reuters: "Prime Minister Kevin Rudd said on Tuesday he had reached agreement with all but one of Australia's states on major health reforms which he hopes will spearhead his 2010 re-election campaign. Failure to clinch the $51 billion deal, which will see the government become the nation's main health funder, would have fueled perceptions Rudd has been unable to deliver on reform promises that propelled him to power in 2007" (Taylor, 4/20).

21 Apr 2010

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

21 Apr 2010

CorMedix receives patent for Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiorenal disease, today announced that the U.S. Patent and Trademark Office has issued a patent for the use of Neutrolin for preventing infection and clotting in hemodialysis catheters.

21 Apr 2010

A Selection of Today's Opinions: AIDS endures; Conservatives' changing views of the individual mandate; Concerns for doctors

AIDS endures right here in the U.S.A.: our outpatient clinics are bursting at the seams, and new cases show up daily. A million domestic stories are languishing untold, but they are not the operatic tragedies we have grown used to (Dr. Abigail Zuger, 4/19).

21 Apr 2010

White House touts health tax credits, some consumers question costs

"More than 4 million postcards were mailed Monday to small-business owners, touting a tax credit in the new healthcare law that many of them are eligible to receive. The mass mailing is the first step in an aggressive sales and information campaign planned by the White House in an effort to blunt criticism of the law."

21 Apr 2010

FDA approves Lupin Pharmaceuticals' Imipramine Pamoate capsules

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg strengths. Commercial shipments of the product have already commenced.

21 Apr 2010

Guardian accreditation confirms that quality out-of-home care costs

Barnardos Australia today becomes the first child welfare agency to be re-accredited under NSW standards as an agency designated to arrange out-of-home care for children and young people. Barnardo's is also the first agency to pilot the new accreditation system, administered by the Children's Guardian, which groups 22 child focused standards into four quality areas.

20 Apr 2010

Coffs Harbour sports course to reduce injuries

In an effort to reduce sporting injuries, Sports Medicine Australia (SMA) NSW will hold an accredited Level 1 Sports Trainer course in Coffs Harbour on May 22 and 23.

20 Apr 2010

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix' internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

20 Apr 2010

ForteBio introduces new Octet QK(e) instrumentation system

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.

20 Apr 2010

AMRI extends and expands research collaboration with CHDI Foundation

AMRI announced today the five year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc. (CHDI), focused on the discovery of new therapeutic agents for the treatment of Huntington's disease (HD).

20 Apr 2010

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).

20 Apr 2010

Aeterna Zentaris raises $13.7M through registered direct offering

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.

20 Apr 2010

NeoPharm commences enrollment in Phase II clinical trial of LE-DT for pancreatic cancer

NeoPharm, Inc., announced today that it has started enrolling patients in its Phase II clinical trial for liposome entrapped docetaxel (LE-DT), as a frontline treatment of pancreatic cancer patients with locally advanced or metastatic disease. LE-DT is a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®.

20 Apr 2010

Meridian Bioscience's second-quarter net sales down 6% to $31.1M

Net sales for the second quarter of fiscal 2010 were $31,147,000 as compared to $33,280,000 for the same period of the prior fiscal year, a decrease of 6%. Net earnings for the second quarter of fiscal 2010 were $5,980,000 or $0.15 per diluted share, decreases of 18% and 17%, respectively, compared to the second quarter of fiscal 2009. Diluted common shares outstanding for fiscal 2010 and 2009 were 41,177,000 and 41,133,000, respectively.

20 Apr 2010